Japan is the second major market where Kisunla has received approvalKisunla was first approved in the United States in July 2024INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as peopl ...

Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business following a similar trajectory.Nov. 30, 2022, will go down as a defining moment in modern history. That's the day OpenAI released ChatGPT to the masses. Just like that, euphoria about artificial intelligence (AI) took over the world.One of the biggest beneficiaries of the AI boom has been semiconductor specialist Nvidia. If you had bought shares of Nvidia on the same day that ChatGPT was intr ...

文章核心观点 - 该文章是一名全职分析师撰写的,旨在为其投资组合提供独特的见解和知识 [1] - 分析师表示自己没有持有任何相关公司的股票、期权或类似衍生工具,也没有在未来72小时内进行任何此类交易的计划 [1] - 文章仅提供信息性分析,不构成专业投资建议,投资者在进行任何投资前应进行深入研究并尽职调查,因为交易存在许多风险,包括资本损失 [2] - Seeking Alpha 声明过去的业绩不能保证未来的结果,不会就任何投资是否适合特定投资者提供任何建议或意见,分析师观点可能不代表 Seeking Alpha 的整体立场 [2] 行业相关内容 无 公司相关内容 无

文章核心观点 - 制药公司Eli Lilly是全球最大的制药公司,市值超过8000亿美元,主要得益于其糖尿病新药Mounjaro和Zepbound的快速增长 [1] - 过去12个月Eli Lilly的股价上涨了58%,几乎是标普500指数和纳斯达克综合指数涨幅的两倍 [1] - 分析师认为Eli Lilly可能会在年底前再次提高股息,而不是进行股票拆分 [1] 公司概况 - Eli Lilly自1972年以来一直在稳步提高每股股息,从最初的每季度0.01美元增加到现在的1.30美元(每年5.20美元) [2] - 2015年开始Eli Lilly开始持续提高股息,这可能与其糖尿病新药Trulicity获批上市有关 [2] - 除了糖尿病新药,Eli Lilly的癌症药物Verzenio适应症扩大以及阿尔茨海默治疗药物获批也预示着公司未来还有进一步增长空间 [3] 股息政策 - Eli Lilly每年12月都会宣布提高股息,次年2月中旬除息 [4] - 分析师认为Eli Lilly很可能会在今年12月再次提高股息,这为投资者带来了被动收益的机会 [5]

公司概况 - 公司是一家专注于发掘高增长潜力和价值被低估的投资机会的研究公司 [1] - 公司的研究分析师擅长解读各种新闻、事件、财报等,发现潜在的投资机会和风险 [1] - 公司的研究分析师被TipRanks和Seeking Alpha评为行业顶级分析师 [1] 投资策略 - 公司采取机会主义的投资策略,专注于识别风险收益比较优的增长型投资机会 [1] - 公司倾向于避开过度炒作和估值过高的股票,而是关注那些遭受重创但仍有显著上涨潜力的股票 [1] - 公司的投资组合专注于那些拥有强劲基本面、买入动力和扭亏为盈机会的增长型股票 [2] - 公司的投资组合聚焦于18-24个月内有望实现投资价值的机会 [2]

Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.Berkshire Hathaway recently crossed the $1 trillion market cap, becoming the first non-tech stock to do so. While the stock has given back some gains in recent days and fallen below that threshold, it's still an incredible accomplishment nonetheless.But there's another non-tech stock which could be worth $1 trillion in the near future, and that's Eli Lilly (LLY -0.13%). The healthcare giant ...

Lilly could take a step that's positive for the stock and investors over the long term.Eli Lilly (LLY -0.13%) offers investors the same thing as many other big pharma companies: a certain level of security when it comes to revenue. Since people need their medicines regardless of the economic environment, these players generally are linked to some earnings stability and visibility. But Lilly has stood out from the crowd in recent quarters by also giving investors something that's generally seen more in techn ...

文章核心观点 - 艾利·利利公司(LLY)的股票在过去6个月内上涨了21.1%,而同行业平均上涨10.5% [1] - LLY的新药Mounjaro和Zepbound成为公司2024年的主要收入驱动力,销售额达到66.7亿美元,占总收入的44% [3] - LLY正在积极开发Mounjaro和Zepbound在其他适应症如睡眠呼吸暂停、心力衰竭等的应用,有望进一步提升销售 [4] - LLY新药Kisunla获批治疗早期阿尔茨海默病,有望成为新的销售增长点 [6] - LLY在肥胖症领域有11个新分子正在临床开发,包括2个后期候选药物,有望在2025年获得重要临床数据 [7] - LLY股票估值较行业有溢价,但分析师对其未来业绩预期持乐观态度 [8][9][10] 公司概况 - LLY是一家大型制药公司,在过去5年里股价上涨超过730%,主要得益于其在新药研发,特别是肥胖症领域的出色表现 [10] - LLY正在持续推进新药管线,包括糖尿病、阿尔茨海默病、肥胖症等多个治疗领域,并通过并购等方式不断补充新的发展动力 [6][7][10] - 公司正在大幅投资扩充产能,以满足Mounjaro和Zepbound等新药快速增长的需求 [3] - LLY面临来自诺和诺德(NVO)的竞争压力,但目前仍保持领先地位 [5] 行业概况 - 糖尿病和肥胖症用药是一个快速增长的重要治疗领域,LLY的Mounjaro和Zepbound等新药在这一领域表现出色 [3][5] - 阿尔茨海默病新药研发也是制药行业的重点关注领域,LLY的Kisunla有望在这一领域取得突破 [6] - 整个制药行业正在加大在新药研发、产能扩充等方面的投入,以应对激烈的市场竞争 [3][5][7]

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the door of a trillion-dollar valuation.Right now, there are seven companies in the world with a market capitalization in excess of $1 trillion. Those companies are Apple, Microsoft, Nvidia, Amazon, Alphabet, Saudi Aramco, and Meta Platforms.Considering how integrated technology has become in almost all aspects of daily life, it's not entirely surprising that many of the largest companies in ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this drugmaker have returned +0.2%, compared to the Zacks S&P 500 composite's +1.5% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Lilly falls in, has gained 1.5%. The key question now is: What could be the stock's future direction?Although media report ...